Literature DB >> 26414799

Discarded Human Thymus Is a Novel Source of Stable and Long-Lived Therapeutic Regulatory T Cells.

I E Dijke1,2, R E Hoeppli3, T Ellis1,2, J Pearcey1,2, Q Huang3, A N McMurchy3, K Boer4, A M A Peeters4, G Aubert5, I Larsen1,2, D B Ross2,6, I Rebeyka2,6, A Campbell3, C C Baan4, M K Levings3, L J West1,2,6.   

Abstract

Regulatory T cell (Treg)-based therapy is a promising approach to treat many immune-mediated disorders such as autoimmune diseases, organ transplant rejection, and graft-versus-host disease (GVHD). Challenges to successful clinical implementation of adoptive Treg therapy include difficulties isolating homogeneous cell populations and developing expansion protocols that result in adequate numbers of cells that remain stable, even under inflammatory conditions. We investigated the potential of discarded human thymuses, routinely removed during pediatric cardiac surgery, to be used as a novel source of therapeutic Tregs. Here, we show that large numbers of FOXP3(+) Tregs can be isolated and expanded from a single thymus. Expanded thymic Tregs had stable FOXP3 expression and long telomeres, and suppressed proliferation and cytokine production of activated allogeneic T cells in vitro. Moreover, expanded thymic Tregs delayed development of xenogeneic GVHD in vivo more effectively than expanded Tregs isolated based on CD25 expression from peripheral blood. Importantly, in contrast to expanded blood Tregs, expanded thymic Tregs remained stable under inflammatory conditions. Our results demonstrate that discarded pediatric thymuses are an excellent source of therapeutic Tregs, having the potential to overcome limitations currently hindering the use of Tregs derived from peripheral or cord blood. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26414799     DOI: 10.1111/ajt.13456

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  30 in total

Review 1.  Methods to manufacture regulatory T cells for cell therapy.

Authors:  K N MacDonald; J M Piret; M K Levings
Journal:  Clin Exp Immunol       Date:  2019-04-15       Impact factor: 4.330

Review 2.  Promises and limitations of immune cell-based therapies in neurological disorders.

Authors:  Xiaoming Hu; Rehana K Leak; Angus W Thomson; Fang Yu; Yuguo Xia; Lawrence R Wechsler; Jun Chen
Journal:  Nat Rev Neurol       Date:  2018-09       Impact factor: 42.937

Review 3.  Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs.

Authors:  Antoine Sicard; Megan K Levings; David W Scott
Journal:  Am J Transplant       Date:  2018-04-21       Impact factor: 8.086

4.  Regulatory T Cells for the Induction of Transplantation Tolerance.

Authors:  Weitao Que; Xiao-Kang Li
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor.

Authors:  Katherine G MacDonald; Romy E Hoeppli; Qing Huang; Jana Gillies; Dan S Luciani; Paul C Orban; Raewyn Broady; Megan K Levings
Journal:  J Clin Invest       Date:  2016-03-21       Impact factor: 14.808

6.  Coexpression of FOXP3 and a Helios isoform enhances the effectiveness of human engineered regulatory T cells.

Authors:  Amara Seng; Kelsey L Krausz; Dong Pei; Devin C Koestler; Ryan T Fischer; Thomas M Yankee; Mary A Markiewicz
Journal:  Blood Adv       Date:  2020-04-14

7.  Cryopreservation timing is a critical process parameter in a thymic regulatory T-cell therapy manufacturing protocol.

Authors:  Katherine N MacDonald; Sabine Ivison; Keli L Hippen; Romy E Hoeppli; Michael Hall; Grace Zheng; I Esme Dijke; Mohammed Al Aklabi; Darren H Freed; Ivan Rebeyka; Sanjiv Gandhi; Lori J West; James M Piret; Bruce R Blazar; Megan K Levings
Journal:  Cytotherapy       Date:  2019-12-03       Impact factor: 5.414

Review 8.  Regulatory T cells: tolerance induction in solid organ transplantation.

Authors:  T Vaikunthanathan; N Safinia; D Boardman; R I Lechler; G Lombardi
Journal:  Clin Exp Immunol       Date:  2017-05-25       Impact factor: 4.330

9.  CAR-Tregs as a Strategy for Inducing Graft Tolerance.

Authors:  Johanna C Wagner; Qizhi Tang
Journal:  Curr Transplant Rep       Date:  2020-07-04

10.  Ectopic FOXP3 Expression in Combination with TGF-β1 and IL-2 Stimulation Generates Limited Suppressive Function in Human Primary Activated Thymocytes Ex Vivo.

Authors:  Jorge Gallego-Valle; Sergio Gil-Manso; Ana Pita; Esther Bernaldo-de-Quirós; Rocío López-Esteban; Marta Martínez-Bonet; Verónica Astrid Pérez-Fernández; Ramón Pérez-Caballero; Carlos Pardo; Juan-Miguel Gil-Jaurena; Rafael Correa-Rocha; Marjorie Pion
Journal:  Biomedicines       Date:  2021-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.